Business
Craig A. Dionne to Speak at BIO International 2015
Craig A. Dionne to Speak at BIO International 2015.
About this update from Rebus Hldgs Inc.
[{"type":"text","content":"\n \n \n Craig A. Dionne to Speak at BIO International 2015\n \n \nCraig A. Dionne to Speak at BIO International 2015\n \n SAN ANTONIO, TX and PHILADELPHIA, PA--(Marketwired - Jun 15, 2015) - GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at BIO International Convention 2015 on Wednesday, June 17, 2015 at 2:00 P.M. in Philadelphia, PA.\n The presentation will run on the Oncology track and will be held in Theatre 4, \"The Incredible Helix\".\n Dr. Dionne stated, \"I am pleased to present the latest news on mipsagargin during the Oncology track at BIO International 2015. This is a significant opportunity to share our Company's story with a wide audience of global biotechnology leaders. I thank the conference organizers for the opportunity.\"\n About Mipsagargin\n Mipsagargin is a prodrug in human clinical trials for several different tumor types. Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until the peptide is removed. The mechanism of action works by targeting the enzyme PSMA, which is highly expressed on the surface of almost all cancer tumor vasculature, including those of glioblastoma. PSMA recognizes and removes the peptide, releasing the active ingredient 12ADT into the cell and bringing about cell death. The prodrug delivery system ensures that mipsagargin is activated only within the tumor, providing greater anti-tumor efficacy and minimizing side effects. \n About The Bio International Convention\n The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities\n About GenSpera\n GenSpera, Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera's l...